These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23167987)

  • 1. A qualitative assessment of cross-cultural adaptation of intermediate measures for schizophrenia in multisite international studies.
    Gonzalez JM; Rubin M; Fredrick MM; Velligan DI
    Psychiatry Res; 2013 Apr; 206(2-3):166-72. PubMed ID: 23167987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cultural adaptability of intermediate measures of functional outcome in schizophrenia.
    Velligan DI; Rubin M; Fredrick MM; Mintz J; Nuechterlein KH; Schooler NR; Jaeger J; Peters NM; Buller R; Marder SR; Dube S
    Schizophr Bull; 2012 May; 38(3):630-41. PubMed ID: 21134973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The reliability and validity of the MATRICS functional assessment battery.
    Velligan DI; Fredrick M; Mintz J; Li X; Rubin M; Dube S; Deshpande SN; Trivedi JK; Gautam S; Avasthi A; Kern RS; Marder SR
    Schizophr Bull; 2014 Sep; 40(5):1047-52. PubMed ID: 24214931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity.
    Keefe RS; Poe M; Walker TM; Kang JW; Harvey PD
    Am J Psychiatry; 2006 Mar; 163(3):426-32. PubMed ID: 16513863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
    Green MF; Nuechterlein KH; Kern RS; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Seidman LJ; Stover E; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):221-8. PubMed ID: 18172017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning.
    Ventura J; Welikson T; Ered A; Subotnik KL; Keefe RSE; Hellemann GS; Nuechterlein KH
    Early Interv Psychiatry; 2020 Feb; 14(1):106-114. PubMed ID: 31183960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms.
    Bowie CR; Reichenberg A; Patterson TL; Heaton RK; Harvey PD
    Am J Psychiatry; 2006 Mar; 163(3):418-25. PubMed ID: 16513862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validating the measurement of real-world functional outcomes: phase I results of the VALERO study.
    Harvey PD; Raykov T; Twamley EW; Vella L; Heaton RK; Patterson TL
    Am J Psychiatry; 2011 Nov; 168(11):1195-201. PubMed ID: 21572166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia.
    Green MF; Schooler NR; Kern RS; Frese FJ; Granberry W; Harvey PD; Karson CN; Peters N; Stewart M; Seidman LJ; Sonnenberg J; Stone WS; Walling D; Stover E; Marder SR
    Am J Psychiatry; 2011 Apr; 168(4):400-7. PubMed ID: 21285142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia.
    Reise SP; Ventura J; Keefe RS; Baade LE; Gold JM; Green MF; Kern RS; Mesholam-Gately R; Nuechterlein KH; Seidman LJ; Bilder R
    Psychol Assess; 2011 Mar; 23(1):245-61. PubMed ID: 21381848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
    Buchanan RW; Keefe RS; Lieberman JA; Barch DM; Csernansky JG; Goff DC; Gold JM; Green MF; Jarskog LF; Javitt DC; Kimhy D; Kraus MS; McEvoy JP; Mesholam-Gately RI; Seidman LJ; Ball MP; McMahon RP; Kern RS; Robinson J; Marder SR
    Biol Psychiatry; 2011 Mar; 69(5):442-9. PubMed ID: 21145041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms.
    Leifker FR; Bowie CR; Harvey PD
    Schizophr Res; 2009 Nov; 115(1):82-7. PubMed ID: 19775869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing an international scoring system for a consensus-based social cognition measure: MSCEIT-managing emotions.
    Hellemann GS; Green MF; Kern RS; Sitarenios G; Nuechterlein KH
    Psychol Med; 2017 Oct; 47(14):2494-2501. PubMed ID: 28443534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computerized cognitive remediation training for schizophrenia: an open label, multi-site, multinational methodology study.
    Murthy NV; Mahncke H; Wexler BE; Maruff P; Inamdar A; Zucchetto M; Lund J; Shabbir S; Shergill S; Keshavan M; Kapur S; Laruelle M; Alexander R
    Schizophr Res; 2012 Aug; 139(1-3):87-91. PubMed ID: 22342330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-cultural adaptation and psychometric properties of the Chinese version of the Functional Remission of General Schizophrenia (FROGS) scale and the four-item version (mini-FROGS) among people with schizophrenia.
    Wang WL; Zhou YQ; Mao YY; Qu P
    Asian J Psychiatr; 2020 Jan; 47():101871. PubMed ID: 31739130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive Assessment Interview (CAI): Validity as a co-primary measure of cognition across phases of schizophrenia.
    Ventura J; Subotnik KL; Ered A; Hellemann GS; Nuechterlein KH
    Schizophr Res; 2016 Apr; 172(1-3):137-42. PubMed ID: 26852403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls.
    Segarra N; Bernardo M; Gutierrez F; Justicia A; Fernadez-Egea E; Allas M; Safont G; Contreras F; Gascon J; Soler-Insa PA; Menchon JM; Junque C; Keefe RS
    Eur Psychiatry; 2011 Mar; 26(2):69-73. PubMed ID: 20435446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
    Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
    Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case control study of association between cognition and functional capacity in schizophrenia.
    Narayanan SS; Bhatia T; Velligan DI; Nimgaonkar VL; Deshpande SN
    Schizophr Res; 2015 Dec; 169(1-3):165-168. PubMed ID: 26527248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.